Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin s...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 112
- Registration Number
- NCT05342532
- Locations
- 🇺🇸
Mount Sinai Union Square Division of Digestive Diseases, New York, New York, United States
Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 20
- Registration Number
- NCT05309928
- Locations
- 🇺🇸
UAB, Birmingham, Alabama, United States
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 10
- Registration Number
- NCT05302531
- Locations
- 🇫🇷
CHRU Nancy, Vandœuvre-lès-Nancy, Lorraine, France
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 388
- Registration Number
- NCT05250050
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 600
- Registration Number
- NCT05237115
- Locations
- 🇨🇳
Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 672
- Registration Number
- NCT05189444
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China
Primary Care Amoxicillin Challenge
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- State University of New York at Buffalo
- Registration Number
- NCT05165212
Helicobacter Pylori Eradication and Follow-up
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 4447
- Registration Number
- NCT05061732
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 1300
- Registration Number
- NCT05049902
- Locations
- 🇨🇳
Maternity and Child Care Health Center of Dezhou, Dezhou, Shandong, China
🇨🇳Heze Municipal 3rd people's hospital, Heze, Shandong, China
🇨🇳Qilu hosipital, Jinan, Shandong, China
Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 233
- Registration Number
- NCT05035186
- Locations
- 🇪🇬
Alexandria University., Alexandria, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.